FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Ear Infections

Cedax (ceftibuten) (by Schering-Plough), Approved December 1995
Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis

Floxin otic (by Daiichi Sankyo), Approved December 1997
Treatment for otitis media

Xtoro (finafloxacin otic suspension) 0.3% (by Alcon), Approved December 2014
For the treatment of acute otitis externa

Ear Infections (Pediatric)

Otiprio (ciprofloxacin otic suspension) (by Otonomy), Approved December 2015
For the treatment of pediatrics with bilateral otitis media with effusion undergoing tympanostomy tube placement

Rocephin (by Roche), Approved January 1998
Treatment for pediatric otitis media

Effects of Chemotherapy

Akynzeo (netupitant and palonosetron) (by Helsinn), Approved October 2014
For the prevention of chemotherapy-induced nausea and vomiting

Sustol (granisetron) (by Heron Therapeutics), Approved August 2016
For the prevention of chemotherapy-induced nausea and vomiting

Syndros (dronabinol oral solution) (by Insys Therapeutics), Approved July 2016
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy

Varubi (rolapitant) (by Tesaro), Approved September 2015
For the prevention of delayed nausea and vomiting associated with chemotherapy

Vistogard (uridine triacetate) (by Wellstat Therapeutics), Approved December 2015
For the emergency treatment of patients with a fluorouracil or capecitabine overdose

Zuplenz (ondansetron oral soluble film) (by Strativa Pharmaceuticals), Approved July 2010
For the prevention of post-operative, chemotherapy and radiotherapy induced nausea and vomiting

Elevated Triglycerides (Hypertriglyceridemia)

Epanova (omega-3-carboxylic acids) (by AstraZeneca), Approved May 2014
For the treatment of severe hypertriglyceridemia

Epilepsy

Briviact (brivaracetam) (by UCB), Approved February 2016
For the treatment of partial onset seizures related to epilepsy

Carnexiv (carbamazepine) (by Lundbeck), Approved October 2016
replacement therapy when oral administration is not feasible, in adults with seizures

Depakote (divalproex sodium) (by Abbott Laboratories), Approved June 1996
Treatment for epilepsy

Fycompa (perampanel) (by Eisai), Approved October 2012
For the treatment of partial-onset seizures with or without secondarily generalized seizures

Keppra (by UCB), Approved November 1999
Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy

Lamictal Chewable Dispersible Tablets (by GlaxoSmithKline), Approved August 1998
Treatment for Epilepsy

Neurontin (gabapentin) oral solution (by Parke-Davis), Approved March 2000
Treatment of partial seizures in adults with epilepsy

Oxtellar XR (oxcarbazepine extended release) (by Supernus Pharmaceuticals), Approved October 2012
For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age

Tegretol (carbamazepine) (by Ciba Pharmaceuticals), Approved March 1996
Treatment for young children with epilepsy

Tegretol XR (carbamazepine) (by Ciba-Geigy), Approved May 1996
Anti-epileptic treatment

Trileptal (oxcarbazepine) Tablets (by Novartis), Approved January 2000
Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults)

Vimpat (lacosamide) (by Schwarz Pharma), Approved October 2008
For the treatment of partial-onset seizures in adults with epilepsy

Zonegran (zonisamide) Capsules (by Dainippon Pharmaceutical), Approved March 2000
Adjunctive therapy for treatment of partial seizures in adults with epilepsy

Epilepsy (Pediatric)

Briviact (brivaracetam) (by UCB), Approved February 2016
For the treatment of partial onset seizures related to epilepsy

Fycompa (perampanel) (by Eisai), Approved October 2012
For the treatment of partial-onset seizures with or without secondarily generalized seizures

Oxtellar XR (oxcarbazepine extended release) (by Supernus Pharmaceuticals), Approved October 2012
For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age

Erectile Dysfunction

INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) (by SmithKline Beecham), January 1997
Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children

Cialis (tadalafil) (by Eli Lilly), Approved December 2003
Oral agent for the treatment for erectile dysfunction

EDEX (by Schwarz Pharma), Approved June 1997
Treatment for erectile dysfunction

Levitra (vardenafil) (by Bayer, GlaxoSmithKline), Approved September 2003
For the treatment of erectile dysfunction related to sexual activity in men

Stendra (avanafil) (by Vivus), Approved April 2012
For the treatment of erectile dysfunction

Stendra (avanafil) (by Vivus), Approved April 2012
For the treatment of erectile dysfunction

Esophageal Cancer

Photodynamic Therapy (by Sanofi-aventis), Approved January, 1996
Photodynamic therapy device for the treatment of esophageal cancer

Eye Disorders/Infections

Bepreve (bepotastine besilate ophthalmic solution) (by Ista Pharmaceuticals), Approved September 2009
For the treatment of itching associated with allergic conjunctivitis

Cystaran (cysteamine hydrochloride) (by Sigma Tau Pharmaceuticals), Approved October 2012
For the treatment of corneal cystine crystal accumulation due to cystinosis

Eylea (aflibercept) (by Regeneron Pharmaceuticals), Approved November 2011
For the treatment of neovascular (wet) age-related macular degeneration

Humira (adalimumab) (by Abbvie), Approved July 2016
For the treatment of uveitis

Jetrea (ocriplasmin) (by Thrombogenics), Approved October 2012
For the treatment of symptomatic vitreomacular adhesion

OcuHist (by Pfizer), Approved January 1996
Over-the-counter antihistamine eye drop

Omidria (phenylephrine and ketorolac injection) (by Omeros), Approved June 2014
For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain

Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) (by Greer Labs), Approved April 2014
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis

Zerviate (cetirizine ophthalmic solution 0.24%) (by NicOx), Approved May 2017
For the treatment of ocular itching associated with allergic conjunctivitis

Eye Disorders/Infections (Pediatric)

Cystaran (cysteamine hydrochloride) (by Sigma Tau Pharmaceuticals), Approved October 2012
For the treatment of corneal cystine crystal accumulation due to cystinosis